<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05104372</url>
  </required_header>
  <id_info>
    <org_study_id>16/136/109-AAIP-NW</org_study_id>
    <nct_id>NCT05104372</nct_id>
  </id_info>
  <brief_title>Hypertonic Saline Nasal Irrigation and Gargling (HSNIG) for Suspected COVID-19 in Pakistan</brief_title>
  <acronym>HSNIG</acronym>
  <official_title>Hypertonic Saline Nasal Irrigation and Gargling (HSNIG) for Suspected COVID-19: Pragmatic, Web-based Bayesian Adaptive Randomised Controlled Trial in Pakistan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Allergy and Asthma Institute, Pakistan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Allergy and Asthma Institute, Pakistan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nasal washing (washout) followed by gargles with hypertonic saline (HSNIG) is believed to be&#xD;
      effective in reducing the duration of illness in those with clinically suspected or confirmed&#xD;
      COVID-19 being managed at home, and also is effective in reducing complications of COVID-19&#xD;
      and onward household transmission.&#xD;
&#xD;
      This study plans to investigate whether the use of HSNIG performed by adults with symptoms&#xD;
      consistent with COVID-19 reduces the duration of symptoms when compared to participants&#xD;
      managed using standard care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND&#xD;
&#xD;
      Analysis of data from the recent &quot;Edinburgh and Lothians Viral Intervention Study&quot; (ELVIS)&#xD;
      pilot randomized controlled trial (RCT) indicates that hypertonic saline nasal irrigation and&#xD;
      gargling (HSNIG) reduced the duration of coronavirus upper respiratory tract infection (URTI)&#xD;
      by an average of two-and-a-half days. As such, it may offer a potentially safe, effective and&#xD;
      scalable intervention in those with Coronavirus Disease-19 (COVID-19) following infection&#xD;
      with the beta-coronavirus Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).&#xD;
&#xD;
      The researchers recently reported that epithelial cells mount an antiviral effect by&#xD;
      producing hypochlorous acid (HOCl) from chloride ions. HOCl is the active ingredient in&#xD;
      bleach. Epithelial cells have this innate antiviral immune mechanism to clear viral&#xD;
      infections. Since bleach is effective against all virus types, it was tested to see whether a&#xD;
      range of DNA, RNA, enveloped and non-enveloped viruses were inhibited in the presence of&#xD;
      chloride ions supplied via salt (NaCl). All the viruses tested were inhibited in the presence&#xD;
      of NaCl. The human viruses which were tested included: DNA/enveloped: herpes simplex virus;&#xD;
      RNA/enveloped: human coronavirus 229E (HCoV-229E), respiratory syncytial virus, influenza A&#xD;
      virus; and RNA/non-enveloped: coxsackievirus B3.&#xD;
&#xD;
      In COVID-19, high titers of SARS-CoV-2 are detectable in the upper respiratory tract of&#xD;
      asymptomatic and symptomatic individuals. The titers are higher in the nose than the throat&#xD;
      suggesting measures that control the infection and viral shedding will help reduce&#xD;
      transmission.&#xD;
&#xD;
      Till the time a significant proportion of the world population is vaccinated against&#xD;
      COVID-19, a safe and effective intervention is needed that can be implemented globally. The&#xD;
      in-vitro data gives the evidence that NaCl has an antiviral effect that works across viral&#xD;
      types. The findings from this post-hoc analysis of ELVIS need to be interpreted with caution.&#xD;
      These data do however suggest that HSNIG may have a role to play in reducing symptoms and&#xD;
      duration of illness in COVID-19.&#xD;
&#xD;
      HYPOTHESES Primary: HSNIG is effective in reducing the duration of illness in those with&#xD;
      clinically suspected or confirmed COVID-19 being managed at home.&#xD;
&#xD;
      Secondary: HSNIG is effective in reducing complications of COVID-19 and onward household&#xD;
      transmission.&#xD;
&#xD;
      INTERVENTION The Intervention group will be suspected or confirmed COVID-19 infected&#xD;
      individuals. They will make hypertonic saline at home, and perform nasal washing and gargles,&#xD;
      as per instructions and study videos, which will be available to be viewed by the&#xD;
      intervention group only, in the study website &quot;www.nasalwash.pk&quot;. This will be used as&#xD;
      required to a maximum of 12 times/day for a maximum of 14 days. Participants are informed&#xD;
      that symptoms might reduce after HSNIG, but may return after a while. Symptoms could hence&#xD;
      return as early as 30 minutes to many hours after HSNIG. Participants will be advised to&#xD;
      perform HSNIG as soon as symptoms return, and as many times as needed (but not more than 12&#xD;
      times/day) until they become symptom-free, or until the end of their study participation&#xD;
      (either on day 14, or on admission to hospital or on withdrawal from the study), and follow&#xD;
      standard advice from their physicians or the Pakistan Government website on personal and&#xD;
      household hygiene and social distancing: http://www.covid.gov.pk/prevention.&#xD;
&#xD;
      CONTROL The participants randomized to the control arm will be asked to perform ablution,&#xD;
      which includes washing of the nose by the prescribed Islamic method with plain water,&#xD;
      (instructions and study videos are available to be viewed by the control group in the study&#xD;
      website) and to follow the guidance on personal and household hygiene and social distancing&#xD;
      as advised by the Ministry of Health, Government of Pakistan, at&#xD;
      http://www.covid.gov.pk/prevention.&#xD;
&#xD;
      OBJECTIVES Primary Objective To investigate whether the use of HSNIG performed by adults with&#xD;
      symptoms consistent with COVID-19 reduces the duration of symptoms when compared to&#xD;
      participants managed using standard care.&#xD;
&#xD;
      Secondary Objectives&#xD;
&#xD;
      To determine the effect of HSNIG on:&#xD;
&#xD;
        1. Severity of all symptoms&#xD;
&#xD;
        2. Duration and severity of individual symptoms&#xD;
&#xD;
        3. Over-the-counter medication use&#xD;
&#xD;
        4. Contact with primary care, or Covid19 emergency helpline.&#xD;
&#xD;
        5. Hospital emergency attendance and/or hospital admission, and diagnosis&#xD;
&#xD;
        6. Number of household contacts infected&#xD;
&#xD;
        7. Side-effect of HSNIG.&#xD;
&#xD;
      ENDPOINTS Primary Endpoint Self-reported time to resolution as assessed by completion of the&#xD;
      validated self-reported UK-adapted short form of the Wisconsin Upper Respiratory Symptom&#xD;
      Survey (WURSS-24) which will be used to collect daily symptom data.&#xD;
&#xD;
      Secondary Endpoints&#xD;
&#xD;
        1. Severity of all symptoms&#xD;
&#xD;
        2. The length of time for individual symptoms to resolve&#xD;
&#xD;
        3. Severity of individual symptoms&#xD;
&#xD;
        4. Contacting healthcare.&#xD;
&#xD;
        5. Participants needing physician appointments.&#xD;
&#xD;
        6. Participants attending hospital&#xD;
&#xD;
        7. Length of stay in hospital, if admitted&#xD;
&#xD;
        8. Number of participants reporting over the counter medication use&#xD;
&#xD;
        9. Reduction in transmission to household contacts&#xD;
&#xD;
       10. Number of participants reporting side effects of nasal irrigation&#xD;
&#xD;
       11. Types and severity of side effects reported&#xD;
&#xD;
      STUDY DESIGN&#xD;
&#xD;
      This study is a pragmatic, non-CTIMP, web-based, Bayesian adaptive randomized controlled&#xD;
      trial (RCT) of HSNIG vs. standard care in adults over 18 years of age with suspected or&#xD;
      confirmed COVID-19. The study will run throughout the course of the COVID-19 pandemic until&#xD;
      numbers have been recruited for sufficient analysis, or until 30th of November 2021.&#xD;
      Participants are recruited within 5 days of developing COVID-19 symptoms by use of the study&#xD;
      website (&quot;www.nasalwash.pk&quot;), study advertising through traditional media such as radio and&#xD;
      internet advertisements, as well as social media. Paper leaflets will be distributed at&#xD;
      chemists, doctors' clinics, COVID testing centers, and through organizations working with&#xD;
      COVID patients. For the purposes of this study, symptoms or diagnosis of COVID-19 are defined&#xD;
      as at least one of the following symptoms, which include:&#xD;
&#xD;
        -  Respiratory symptoms, such as cough and shortness of breath&#xD;
&#xD;
        -  Fever&#xD;
&#xD;
        -  Muscle pain&#xD;
&#xD;
        -  Headache&#xD;
&#xD;
        -  Sore throat&#xD;
&#xD;
        -  New loss of taste or smell&#xD;
&#xD;
        -  Severe fatigue&#xD;
&#xD;
        -  Nausea or vomiting&#xD;
&#xD;
        -  Diarrhea&#xD;
&#xD;
        -  Congestion or runny nose&#xD;
&#xD;
      Willing participants will be directed by the study advertising to a study specific webpage at&#xD;
      &quot;www.nasalwash.pk&quot;, where they will be able to access further study information and&#xD;
      documents, which will include a Patient Information Sheet and a Consent form. All data&#xD;
      including consent will be obtained electronically, details of how the process of electronic&#xD;
      consent will work is given in detail below in the section titled &quot;Consenting Participants&quot;.&#xD;
&#xD;
      After obtaining their electronic consent, they will be randomized automatically by the&#xD;
      software to either the Intervention Group, or the Control Group. They will be provided a&#xD;
      password to a personal area, which will contain an instructional video on whether they will&#xD;
      perform hypertonic saline nasal irrigation and gargles (the intervention group); or do either&#xD;
      nothing, or regularly continue to perform ablution for prayers (the control group). The&#xD;
      affected individual (not more than one participant per household) will be centrally&#xD;
      randomized through an easy to access web-based randomization schedule hosted at the study&#xD;
      data center at the Allergy &amp; Asthma Institute, Pakistan, in collaboration with the Edinburgh&#xD;
      Clinical Trials Unit, University of Edinburgh.&#xD;
&#xD;
      All pre- and post-randomization data will be collected through mobile phone/web-based&#xD;
      questionnaires (see Daily Study Diary, Daily Symptom report, End of Illness questionnaire and&#xD;
      Day 14 questionnaire). Participants will be randomized to either a Control arm of standard&#xD;
      symptomatic care, or an Intervention arm of HSNIG up to 12 times per day for a maximum of 14&#xD;
      days or until asymptomatic, alongside standard symptomatic care. All participants will be&#xD;
      required to complete a daily symptom diary until Day 14 and all participant will be asked to&#xD;
      complete the Day 14 questionnaire, which will establish if any other members of the&#xD;
      participant's household have developed symptoms of COVID-19. If a participant's symptoms&#xD;
      clear before Day 14, they will be invited to complete the End of Illness questionnaire&#xD;
      (healthcare use, adverse events, acceptability, infection in household contacts) on the day&#xD;
      that these symptoms resolve, and continue to fill in the Daily Diary, in case of recurrence&#xD;
      of symptoms until Day 14.&#xD;
&#xD;
      Participants who have been randomized to the Intervention arm, will be directed towards a&#xD;
      password-protected webpage featuring videos and instructions on how to prepare the hypotonic&#xD;
      saline solution and how to perform HSNIG, while those randomized to the Control arm will be&#xD;
      directed towards a password-protected webpage featuring a video and instructions on how to&#xD;
      perform ablution with plain water and gargling, as well as washing the nose other than&#xD;
      ablution, but with plain (salt-free) clean water.&#xD;
&#xD;
      The patients who have been randomized to the intervention arm will be directed to the&#xD;
      instructional video in which it will be explained that they should take 250 ml of clean water&#xD;
      (water which has been boiled and cooled, or filtered or mineral water) in the measuring jug&#xD;
      provided, and add one level teaspoon of salt (6.5 grams) and use this salty water for nasal&#xD;
      washing and gargles. In order to standardize the study, and since sea-salt is not very&#xD;
      commonly available in Pakistan, patients in the intervention arm will be provided sea salt&#xD;
      (or preservative-free sodium chloride) for the treatment by the project, along with a&#xD;
      measuring spoon calibrated at 6.5 grams of salt when filled level, and a graduated container&#xD;
      showing 250 ml. This will be posted to them by courier as soon as they are randomized into&#xD;
      the trial / intervention arm of the study. The addition of 6.5 grams of salt to 250 ml of&#xD;
      water will make a 2.6% saline solution.&#xD;
&#xD;
      At consent, participants will be given the option to consent to the future collection of&#xD;
      samples for COVID-19 serological analysis.&#xD;
&#xD;
      It is also proposed to randomly select approximately a proportion of all participants,&#xD;
      according to availability of funds for testing for SARS-CoV-2 infection by RT-PCR, which will&#xD;
      include a swab sample from the nose and/or the throat. to support the diagnosis of COVID-19.&#xD;
      The selected participants will be informed of the government approved laboratories near their&#xD;
      home which provide the required testing facilities and participants will be asked to pay the&#xD;
      costs of these additional tests up front. The cost of the test and transport to the&#xD;
      laboratory will be reimbursed to the participant after the participant sends the report of&#xD;
      this test to the Allergy and Asthma Institute, Pakistan (AAIP), physically or electronically,&#xD;
      and provides the original receipts of payment. Patients who have already had these tests done&#xD;
      will be excluded from the random selection, and their results collected and recorded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A randomised intervention and a control arm, running in parallel</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to resolution of symptoms</measure>
    <time_frame>2 weeks</time_frame>
    <description>Self-reported time to resolution as assessed by completion of the validated self-reported UK-adapted short form of the Wisconsin Upper Respiratory Symptom Survey (WURSS-24) which will be used to collect daily symptom data</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">405</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention Group HSNIG started within 5 days of symptom onset Number of times HSNIG should be done: As many times as needed (but not more than 12 times/day) PLUS&#xD;
Standard personal, household hygiene and social distancing advice:&#xD;
http://www.covid.gov.pk/prevention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control Group&#xD;
Standard personal, household hygiene and social distancing advice:&#xD;
http://www.covid.gov.pk/prevention</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hypertonic Saline Nasal Irrigation and Gargles (HSNIG)</intervention_name>
    <description>Nasal washout and gargles</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA&#xD;
&#xD;
          -  Adults (â‰¥18 years)&#xD;
&#xD;
          -  Those living within larger cities of Pakistan (for laboratory access)&#xD;
&#xD;
          -  Those self-isolating at home within 5 days of the start of the illness with:&#xD;
&#xD;
               1. Clinical symptoms suggestive of COVID-19 (i.e. those who have at least one of the&#xD;
                  following symptoms: Respiratory symptoms, such as cough and shortness of breath;&#xD;
                  Fever; Muscle pain; Headache; Sore throat; New loss of taste or smell; Severe&#xD;
                  fatigue; Nausea or vomiting; Diarrhoea and Congestion or runny nose OR&#xD;
&#xD;
               2. Those with virologically confirmed SARS-CoV-2 infection and clinical symptoms&#xD;
                  indicative of COVID-19 (as detailed in (a) above).&#xD;
&#xD;
          -  Provision of informed consent&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
          -  Onset of illness (symptoms) more than 5 days&#xD;
&#xD;
          -  Inability to consent&#xD;
&#xD;
          -  Age less than 18 years.&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Immunosuppressed patients Inability to perform HSNIG&#xD;
&#xD;
          -  Those taking part in another interventional medical trial&#xD;
&#xD;
          -  Those with suspected/confirmed COVID-19 in whom hospital admission is recommended&#xD;
&#xD;
          -  Those who do not have access to email / internet&#xD;
&#xD;
          -  Those living in a household with another person currently participating in this study&#xD;
&#xD;
          -  Those who have not provided consent to take part&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aziz Sheikh, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Edinburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>OSMAN M YUSUF, MBBS, PhD</last_name>
    <phone>+923008552557</phone>
    <email>allergypk@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aimal T Rextin, PhD</last_name>
    <phone>+923325331588</phone>
    <email>aimal.rextin@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Allergy and Asthma Institute, Pakistan</name>
      <address>
        <city>Islamabad</city>
        <zip>44000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Osman M Yusuf, MD, PhD</last_name>
      <phone>+92512654445</phone>
      <email>allergypk@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Aimal T Rextin, PhD</last_name>
      <email>aimal.rextin@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 25, 2021</study_first_submitted>
  <study_first_submitted_qc>November 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Allergy and Asthma Institute, Pakistan</investigator_affiliation>
    <investigator_full_name>Osman Yusuf</investigator_full_name>
    <investigator_title>Chief Consultant</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The study is anonymized, and individual participant data (IPD) will not be available to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

